A Phase 2 Study of the Activity and Safety of KD025 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This Phase 2 study will be conducted to evaluate the safety, tolerability, and activity of
400 mg of KD025 once-daily (QD) compared to Best Supportive Care (BSC) in male and
postmenopausal/surgically sterilized female subjects with Idiopathic Pulmonary Fibrosis
(IPF). The primary objectives are to evaluate the:
- Change in forced vital capacity (FVC) from Baseline to 24 weeks after dosing with KD025
400 mg QD in subjects with IPF compared to BSC
- Safety and tolerability of KD025 400 mg QD when administered for 24 weeks to subjects
with IPF compared to BSC